Thyroid Cancer clinical trials at UCSF
1 in progress, 1 open to new patients

  • Safety Study of MGD009 in B7-H3-expressing Tumors

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics (PD) and to evaluate potential anti-tumor activity of MGD009.

    San Francisco, California and other locations

© The Regents of the University of California